Ireland

--:--IST

Latest

Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide

Subscribe

Registers› Irish medicines ›Pierre Fabre Medicament

Medicines register · Ireland

Pierre Fabre Medicament — licensed medicines

10 medicines held by Pierre Fabre Medicament on the Irish market, from the HPRA register.

Source: HPRA open dataset ("Authorised or Transfer Pending Products"), CC BY 4.0. Complete coverage — all 10,336 authorised products are in this register. Synced 20 Sep 2026, 17:51 UTC

Narrow the register Reset

Search within results

Matches brand name, active substance, licence holder and licence number.

Browse by first letter

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Medicine

Active substance

Licence holder

Status

Braftovi 50 mg Hard capsule EU/1/18/1314/001

ENCORAFENIB

Pierre Fabre Medicament

—

Braftovi 75 mg Hard capsule EU/1/18/1314/002

ENCORAFENIB

Pierre Fabre Medicament

—

Ebvallo 2.8 × 10^7 – 7.3 × 10^7 cells/mL dispersion for injection EU/1/22/1700/001

Tabelecleucel

Pierre Fabre Medicament

—

Javlor 25 mg/mL concentrate for solution for infusion EU/1/09/550/1-12

Vinflunine ditartrate

Pierre Fabre Medicament

—

Mektovi 15 mg Film-coated tablet EU/1/18/1315/001

BINMETINIB

Pierre Fabre Medicament

—

Mektovi 45 mg Film-coated tablet EU/1/18/1315/003-004

Binimetinib

Pierre Fabre Medicament

—

NAVELBINE 20 mg soft capsule PA0329/011/001

Vinorelbine

Pierre Fabre Medicament

Marketed

NAVELBINE 30 mg soft capsule PA0329/011/002

Vinorelbine

Pierre Fabre Medicament

Marketed

Nerlynx 40 mg Film-coated tablet EU/1/18/1311/001

Neratinib

Pierre Fabre Medicament

—

Obgemsa 75 mg film-coated tablets EU/1/24/1822/001-006

Vibegron

Pierre Fabre Medicament

—

Cite this view

Priya Life Science (2026). Irish Medicines Register, filtered. Derived from the HPRA open dataset. Retrieved 3 October 2026. https://priyalifescience.com/medicines/company/pierre-fabre-medicament

Download this register

GET /api/export.php?register=medicines-ie&format=csv Try the JSON export →

Regulatory information only — not medical advice. For the authoritative record see the HPRA register directly.